Therapeutische Neoangiogenese

Das therapeutische Potenzial angiogener Wachstumsfaktoren ist seit mehreren Jahrzehnten bekannt [10]. In zahlreichen Untersuchungen konnte für mehrere Gefäßwachstumsfaktoren die Fähigkeit der vermehrten Kapillar- und Kollateralgefäßbildung in Tiermodellen mit myokardialer oder Beinarterienischämie nachgewiesen werden [12]. Diese innovative Form der Behandlung ischämischer Erkrankungen wird als »therapeutische Angiogenese« bezeichnet und könnte als adjuvante oder alternative Behandlung bei fortgeschrittenen Stadien der ischämischen Herzerkrankung oder der peripheren arteriellen Verschlusskrankheit eingesetzt werden.

Literatur

• 1 www.theheart.org: March 2001
• 2 Asahara T, Masuda H, Takahashi T. et al . Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.  Circ Res. 1999;  85 221-228
• 3 Asahara T, Murohara T, Sullivan A. et al . Isolation of putative progenitor endothelial cells for angiogenesis.  Science. 1997;  275 964-967
• 4 Baumgartner I, Pieczek A, Manor O. et al . Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.  Circulation. 1998;  97 1114-1123
• 5 Baumgartner I, Rauh G, Pieczek A. et al . Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor.  Ann Intern Med. 2000;  132 880-884
• 6 Brogi E, Schatteman G, Wu T. et al . Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression.  J Clin Invest. 1996;  97 469-476
• 7 Carmeliet P, Ferreira V, Breier G. et al . Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.  Nature. 1996;  380 435-439
• 8 Chronos N A. The FGF-2 initiating revascularization support trial (FIRST),. ACC Clinical Trials 2000
• 9 Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors.  Nat Med. 1999;  5 1359-1364
• 10 Folkman J. Tumor angiogenesis: Therapeutic implications.  N Engl J Med. 1971;  285 1182-1186
• 11 Henry T D, Annex B H, Azrin M A. et al . Double blind, Placebo controlled trial of recombinant human vascular endothelial growth factor - the VIVA trial.  J Am Coll Cardiol. 1999;  33 384A
• 12 Isner J M. Therapeutic angiogenesis: a new frontier for vascular therapy.  Vasc Med. 1996;  1 79-87
• 13 Isner J M, Baumgartner I, Rauh G. et al . Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.  J Vasc Surg. 1998;  28 964-973
• 14 Isner J M, Pieczek A, Schainfeld R. et al . Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.  Lancet. 1996;  348 370-374
• 15 Isner J M, Walsh K, Symes J. et al . Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease.  Hum Gene Ther. 1996;  7 959-988
• 16 Kobayashi T, Hamano K, Li T S. et al . Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model.  J Surg Res. 2000;  89 189-195
• 17 Kornowski R, Fuchs S, Baffour R. et al . Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia.   Eur Heart J. 2000;  21 356
• 18 Laham R J, Chronos N A, Pike M. et al . Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study.  J Am Coll Cardiol. 2000;  36 2132-2139
• 19 Laham R J, Sellke F W, Edelman E R. et al . Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial.  Circulation. 1999;  100 1865-1871
• 20 Laitinen M, Makinen K, Manninen H. et al . Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia.  Hum Gene Ther. 1998;  9 1481-1486
• 21 Lazarous D F, Scheinowitz M, Shou M. et al . Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart.  Circulation. 1995;  91 145-153
• 22 Lazarous D F, Unger E F, Epstein S E. et al . Effect of basic fibroblast growth factor on lower extremity blood flow in patients with intermittent claudication: preliminary results.  Circulation. 1998;  98 I-456
• 23 Lederman R J. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication: Results after 180 days. 50th Congress of the American College of Cardiology. Orlando 2001
• 24 Lehrman S. Virus treatment questioned after gene therapy death.  Nature. 1999;  401 517-518
• 25 Losordo D W, Vale P R, Symes J F. et al . Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.  Circulation. 1998;  98 2800-2804
• 26 Makinen K, Laitinen M, Manninen H. et al . Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA.  Circulation. 1999;  100 I-770
• 27 Neufeld G, Cohen T, Gengrinovitch S. et al . Vascular endothelial growth factor (VEGF) and its receptors.  Faseb J. 1999;  13 9-22
• 28 Nikol S, Engelmann M G, Armeanu S. et al . District-specific influence of vascular endothelial growth factor 165 (VEGF-165) on coronary and peripheral arteries resulting in arteriogenesis or angiogenesis.  Circulation. 1999;  100 I-489
• 29 Papapetropoulos A, Cardena G, Dengler T J. et al . Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.  Lab Invest. 1999;  79 213-223
• 30 Rauh G, Gravereaux E, Pieczek A. et al . Assessment of safety and efficiency of intramuscular gene therapy with VEGF-2 in patients with critical limb ischemia.  Circulation. 1999;  100 I-770
• 31 Risau W. Mechanisms of angiogenesis.  Nature. 1997;  386 671-674
• 32 Rosengart T K, Lee L Y, Patel S R. et al . Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.  Circulation. 1999;  100 468-474
• 33 Rosengart T K, Lee L Y, Port J L. et al . Video assisted epicardially delivery of angiogenic gene therapy to the human myocardium utilizing an Adenovirus vector encoding for VEGF121.  Circulation. 1999;  100 I-770
• 34 Schaper W, Buschmann I. Collateral circulation and diabetes [editorial].  Circulation. 1999;  99 2224-2226
• 35 Schaper W, Schaper J. Collateral circulation: Heart, brain, kidney, limbs. Dortrecht, Netherlands, Kluwer Academic Publishers 1993
• 36 Schumacher B, Pecher P, von Specht B U. et al . Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease.  Circulation. 1998;  97 645-650
• 37 Sellke F W, Laham R J, Edelman E R. et al RP> . Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.  Ann Thorac Surg. 1998;  65 1540-1544
• 38 Symes J F, Losordo D W, Vale P R. et al . Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.  Ann Thorac Surg. 1999;  68 830-836
• 39 Takahashi T, Kalka C, Masuda H. et al . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.  Nat Med. 1999;  5 434-438
• 40 Unger E F, Goncalves L, Epstein S E. et al . Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.  Am J Cardiol. 2000;  85 1414-1419
• 41 Vale P R, Losordo D W, Milliken C E. et al . Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.  Circulation. 2000;  102 965-974
• 42 Waltenberger J. Modulation of growth factor action: implications for the treatment of cardiovascular diseases.  Circulation. 1997;  96 4083-4094
• 43 Wolfe J H, Wyatt M G. Critical and subcritical ischaemia.  Eur J Vasc Endovasc Surg. 1997;  13 578-582
• 44 Yancopoulos G D, Davis S, Gale N W. et al . Vascular-specific growth factors and blood vessel formation.  Nature. 2000;  407 242-248
• 45 Yla-Herttuala S, Martin J F. Cardiovascular gene therapy.  Lancet. 2000;  355 213-222

Korrespondenz